Citi Pharma Limited (PSX: CPHL) has announced a significant milestone in its growth journey with the proposed acquisition of 100% shareholding in Pakheim International Pharmaceuticals (Private) Limited. The transaction, approved by the Company’s Board of Directors, reflects Citi Pharma’s commitment to expanding its operational capabilities, strengthening its market position, and delivering long-term value to stakeholders.
Pakheim International Pharmaceuticals is an established pharmaceutical manufacturer with multiple DRAP-registered products and a fully operational production facility. Through this acquisition, Citi Pharma will gain access to additional manufacturing assets, licenses, and operations that are expected to enhance production capacity and broaden its product portfolio.
The strategic move is designed to create operational synergies, improve production efficiencies, and expand the company’s footprint across both domestic and international markets. Pakheim currently generates annual revenues of approximately PKR 500 million, providing Citi Pharma with an immediate opportunity to strengthen its revenue base while unlocking future growth potential.
As part of its long-term vision, Citi Pharma aims to significantly scale its business over the next five years through portfolio expansion, stronger distribution networks, and continued investment in advanced manufacturing and product development. The acquisition is expected to support these objectives by increasing capacity utilization and creating new opportunities for market expansion.
In addition, the transaction is anticipated to strengthen Citi Pharma’s Active Pharmaceutical Ingredients (API) business. By integrating Pakheim’s operations into its existing ecosystem, the company expects to increase API sales while improving operational efficiency across its manufacturing network.
The acquisition remains subject to the completion of legal, financial, and tax due diligence, as well as the necessary regulatory approvals. Upon completion, Citi Pharma believes the transaction will contribute meaningfully to sustainable growth, innovation, and enhanced shareholder value.
This strategic development reinforces Citi Pharma’s ambition to become a leading pharmaceutical group in the region while continuing to deliver high-quality healthcare solutions and creating lasting value for customers, partners, and investors.
